Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome.
The mechanism of antiphospholipid syndrome (APS) development is still not completely understood. Accumulating evidence indicates that beta(2)-glycoprotein I (beta(2)GPI), is the major target antigen for antiphospholipid (aPL) antibodies, which play a crucial role in the pathogenesis of this autoimmune condition. Knowledge about the molecular structure, biological characteristics and function of beta(2)GPI has been expanding in recent years. In this review, we have focused on some recent important findings on beta(2)GPI and anti-beta(2)GPI antibodies in patients and animal models with APS.
Li
Zhe
Z
Department of Immunology, Allergy and Infectious Diseases, St. George Hospital, University of New South Wales, NSW 2217, Kogarah, Australia.
Krilis
Steven A
SA
D000818:Animals; D016736:Antiphospholipid Syndrome / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D006023:Glycoproteins / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology; D053482:beta 2-Glycoprotein I
D001323:Autoantibodies; D001324:Autoantigens; D006023:Glycoproteins; D053482:beta 2-Glycoprotein I